HCW Biologics
2929 N Commerce Parkway
Miramar
FL
33025
United States
Tel: (954) 842-2024
Website: http://www.hcwbiologics.com/
30 articles about HCW Biologics
-
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
11/14/2023
HCW Biologics Inc. today reported financial results and recent business highlights for its third quarter ended September 30, 2023.
-
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
11/1/2023
HCW Biologics Inc. will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota.
-
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
9/6/2023
HCW Biologics Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City.
-
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
8/11/2023
HCW Biologics Inc. reported financial results and recent business highlights for its second quarter ended June 30, 2023.
-
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
6/14/2023
HCW Biologics Inc. was granted U.S. Patent No. 11,672,826 on June 13, 2023, which contains methods of use claims directed to administering the Company’s clinical-stage bifunctional immunotherapeutic, HCW9218, to treat cancer, including colorectal cancer, breast cancer, ovarian cancer, hepatocellular carcinoma, gastric cancer, urothelial carcinoma, and melanoma.
-
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
5/9/2023
HCW Biologics Inc. today reported financial results and recent business highlights for its first quarter ended March 31, 2023.
-
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
4/27/2023
HCW Biologics Inc. entered into a $26.25 million development line of credit agreement on April 21, 2023.
-
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
4/13/2023
HCW Biologics Inc. today announced that data for the mechanism underlying HCW9218 against solid tumors will be presented at the 2023 Annual Meeting of the American Association for Cancer Research to be held in Orlando, Florida from April 14 – April 19, 2023.
-
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
3/28/2023
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today reported financial results and recent business highlights for its fourth quarter ended December 31, 2022.
-
HCW Biologics Enters CRADA with National Cancer InstituteNCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer
12/8/2022
HCW Biologics Inc. today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.
-
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
12/7/2022
HCW Biologics Inc. was granted U.S. Patent No. 11,518,792 on December 6, 2022, which contains composition claims for a novel multi-function fusion immunotherapeutic.
-
U.S. Patent Issued to HCW Biologics for Foundational Platform Technology
8/3/2022
HCW Biologics Inc. (the “Company”) NASDAQ: HCWB), was granted U.S. Patent 11,401,324 which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains on a scaffold made of an extracellular domain of human tissue factor.
-
HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022
5/23/2022
HCW Biologics Inc. announced today that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will give a corporate presentation on May 25, 2022 at the H.C. Wainwright Annual Global Life Sciences Conference.
-
HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights
5/13/2022
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2022.
-
HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists
5/5/2022
HCW Biologics Inc. is presenting two groups of novel immunotherapeutics created with its proprietary and powerful Tissue factOr-Based fusIon (TOBI™) discovery platform at the 105th Annual Meeting of the American Association of Immunologists (AAI), or Immunology 2022.
-
HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022
4/19/2022
HCW Biologics Inc. announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Third Annual International Conference on Cell and Experimental Biology taking place in Boston, Massachusetts on April 18-20, 2022.
-
HCW Biologics to Present at 2022 Virtual Growth Conference Sponsored by the Maxim Group and M-VestFounder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat”
3/24/2022
HCW Biologics Inc. will participate in Maxim’s 2022 Virtual Growth Conference being held March 28 – 30, 2022.
-
Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218
1/24/2022
HCW Biologics Inc. today announced that the Masonic Cancer Center, University of Minnesota was cleared by the U.S. Food and Drug Administration (FDA) to proceed to evaluate the Company’s lead drug candidate, HCW9218.
-
HCW Biologics’ Founder and CEO Dr. Hing C. Wong Participating in Cambridge Healthtech Institute’s Annual PepTalk Conference 2022
1/19/2022
HCW Biologics Inc. announced that Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, will speak at the Cambridge Healthtech Institute’s 24th Annual PepTalk Conference to be held on January 17-19, 2022.
-
HCW Biologics to Participate in H.C. Wainwright BioConnect Conference January 10 – 13, 2022
1/6/2022
HCW Biologics Inc., a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, announced that members of the HCW Biologics management team will participate in the H.C. Wainwright BioConnect Conference.